Sung Ji Nam
Stock Analyst at Scotiabank
(2.06)
# 2,883
Out of 4,876 analysts
78
Total ratings
41.54%
Success rate
-6.57%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $20.39 | +96.22% | 6 | May 21, 2025 | |
BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.25 | +699.04% | 2 | May 21, 2025 | |
MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.27 | +13.96% | 4 | May 21, 2025 | |
GH Guardant Health | Maintains: Sector Outperform | $52 → $57 | $50.86 | +12.07% | 5 | May 5, 2025 | |
TMO Thermo Fisher Scientific | Maintains: Sector Perform | $650 → $605 | $408.28 | +48.18% | 14 | Apr 25, 2025 | |
BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.25 | +23.08% | 6 | Apr 2, 2025 | |
PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.30 | +54.44% | 5 | Mar 25, 2025 | |
EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $53.65 | +36.07% | 2 | Feb 24, 2025 | |
ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $11.76 | +2.04% | 2 | Feb 13, 2025 | |
WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $352.02 | +27.83% | 2 | Feb 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $88 → $90 | $51.84 | +73.61% | 2 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $35.93 | +72.56% | 5 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $265 | $198.90 | +33.23% | 1 | Dec 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $27.38 | +60.70% | 4 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $19.22 | +82.10% | 4 | Nov 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $94.79 | +73.01% | 9 | Aug 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.14 | +16.85% | 2 | Jun 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.68 | - | 3 | Nov 24, 2020 |
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $20.39
Upside: +96.22%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.25
Upside: +699.04%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.27
Upside: +13.96%
Guardant Health
May 5, 2025
Maintains: Sector Outperform
Price Target: $52 → $57
Current: $50.86
Upside: +12.07%
Thermo Fisher Scientific
Apr 25, 2025
Maintains: Sector Perform
Price Target: $650 → $605
Current: $408.28
Upside: +48.18%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.25
Upside: +23.08%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.30
Upside: +54.44%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $53.65
Upside: +36.07%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $11.76
Upside: +2.04%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $352.02
Upside: +27.83%
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $51.84
Upside: +73.61%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $35.93
Upside: +72.56%
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $198.90
Upside: +33.23%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $27.38
Upside: +60.70%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $19.22
Upside: +82.10%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $94.79
Upside: +73.01%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.14
Upside: +16.85%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.68
Upside: -